1.. Introduction {#s1}
================

The small polyphenol resveratrol (RV), found in various plant-derived sources, including grapes, is considered to contribute to the beneficial effect of red wine in cardiovascular diseases.^[@CVQ355C1]--[@CVQ355C3]^ Pharmacological activities of RV relevant for a putative cardio- and vasoprotective effect include the reduction of platelet aggregation, low-density lipoprotein oxidation, prostaglandin synthesis, and tumour necrosis factor-α-induced activation of endothelial cells, as well as the promotion of endothelial nitric oxide (NO) synthase expression and activity.^[@CVQ355C2],[@CVQ355C3]^ In addition, RV has been shown to inhibit growth-related signalling pathways in cardiac fibroblasts and to protect against ischaemia--reperfusion injury.^[@CVQ355C2],[@CVQ355C3]^ Previous work of our group has demonstrated an antihypertrophic action of RV in angiotensin II (Ang II)-activated vascular smooth muscle cells (VSMCs), which is mediated by a selective inhibition of Akt phosphorylation.^[@CVQ355C4],[@CVQ355C5]^ Angiotensin II is a potent vasoconstrictor, but is also involved in inflammatory processes, vascular oxidative stress, cell growth, and extracellular matrix deposition, promoting endothelial dysfunction and vascular remodelling.^[@CVQ355C6],[@CVQ355C7]^ In the vessel wall, VSMCs are the principal target cells of Ang II in which it promotes contraction contraction, cell growth (hypertrophy), migration, and increased extracellular matrix deposition via activation of the Ang II type 1 AT~1~ receptor.^[@CVQ355C7]^ In VSMCs, the cellular signalling pathways mediating hypertrophy are complex. Important steps are the activation of NAD(P)H oxidase, a major source of cellular reactive oxygen species (ROS), and the transactivation of the epidermal growth factor (EGF) receptor (EGF-R) in a ROS- and c-Src-dependent manner.^[@CVQ355C6]--[@CVQ355C9]^ Downstream of the EGF-R, Akt and extracellular signal-regulated kinase (ERK) signalling pathways are activated.^[@CVQ355C9]^ We have previously shown that RV does not interfere with the transactivation of the EGF-R in Ang II-activated VSMCs when inhibiting Akt phosphorylation. In accordance with this, EGF-induced Akt phosphorylation was also inhibited by RV in VSMCs.^[@CVQ355C5]^ Thus, RV interferes with the signalling towards Akt downstream of the EGF-R in Ang II- or EGF-activated VSMCs. The exact mode of action of RV in VSMCs has remained elusive, although some data have suggested activation of the redox-sensitive protein-tyrosine phosphatase (PTP) Shp2 (Src homology-2-containing protein-tyrosine phosphatase-2) as a mechanism.^[@CVQ355C5]^

Many activities of RV that are thought to contribute to its cardio- and vasoprotective effect, including the activation of redox-sensitive PTPs, such as Shp2, may be explained by its antioxidant activity.^[@CVQ355C2]^ ROS are involved in cell signaling, leading to cell growth and migration, activation of MMPs, altered function of many kinases and phosphatases, and activation of pro-inflammatory transcription factors.^[@CVQ355C10]^ In addition, ROS oxidize low-density lipoprotein and may inactivate NO.^[@CVQ355C11]^ In VSMCs, the most important source of ROS are the NAD(P)H oxidases Nox1 and Nox4.^[@CVQ355C12]--[@CVQ355C14]^ Nox1 is highly expressed in proliferating VSMCs and is activated by a variety of growth factors, such as Ang II and platelet-derived growth factor, contributing to their activation of p38 mitogen-activated protein kinase and Akt.^[@CVQ355C13],[@CVQ355C15],[@CVQ355C16]^ The function of Nox4, the only constitutively active NAD(P)H oxidase, is less clear.^[@CVQ355C15],[@CVQ355C16]^ In VSMCs, Nox4 was found within distinct subcellular locations, such as the nucleus or the endoplasmic reticulum, but also at focal adhesions where the transactivated EGF-R and phosphatidylinositol 3-kinase (PI3K) can be found after Ang II stimulation.^[@CVQ355C15]--[@CVQ355C18]^ While Nox1 is known to be required for Ang II-induced EGF-R transactivation, little is known how the EGF-activated EGF-R induces ROS production^[@CVQ355C19],[@CVQ355C20]^ that may lead to PTP oxidation and signal transduction.^[@CVQ355C21]^

The aim of this study, therefore, was to investigate the following: (i) whether RV reduces the ROS level in or H~2~O~2~ released from Ang II- or EGF-activated VSMCs; (ii) whether Nox1 or Nox4 proteins, or ROS in general, are required for the phosphorylation of Akt downstream of the EGF-R; and thus (iii) whether RV may act directly or indirectly as an 'antioxidant' when inhibiting the phosphorylation of Akt.

2.. Methods {#s2}
===========

2.1. Reagents {#s2a}
-------------

Materials were obtained from the following suppliers: antibodies against phospho-Akt (Ser^473^) and phospho-p38 were from Cell Signaling Technology, anti-tubulin antibody was obtained from Santa Cruz Biotechnology. Resveratrol, Ang II, diphenyleneiodonium (DPI) and *N*-acetyl-cysteine (NAC) were purchased from Sigma-Aldrich. Epidermal growth factor was obtained from Upstate. 2′,7′-Dichlorodihydrofluorescein-diacetate (H~2~DCF-DA) and the Amplex Red™ reagent were from Molecular Probes/Invitrogen. The blocking peptide for Nox1 (Nox2 is not expressed in rat VSMCs;^[@CVQ355C22]^ and own unpublished results), gp91ds-tat, was \[H\]-RKKRRQRRRCSTRIRRQL-NH~2~, and the control peptide used was \[H\]-RKKRRQRRRAGAGAGAGA-NH2, both from CASLO Laboratory ApS. All chemicals used for the synthesis of RV derivatives, unless otherwise stated, were analytical grade and obtained from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany), TCI Europe (Zwijndrecht, Belgium) and Apollo Scientific Limited (Bredbury, UK) and used without further purification.

2.2. Cultivation of cells {#s2b}
-------------------------

The VSMCs were provided by Drs Kathy K. Griendling and Dan Sorescu (Emory University School of Medicine) and were obtained by three independent isolations from male Sprague--Dawley rat (200--250 g, 5--8 weeks old) thoracic aortas by enzymatic digestion as described previously.^[@CVQ355C8],[@CVQ355C23]^ Cells were grown in phenol red-free Dulbecco\'s modified Eagle\'s medium supplemented with 10% calf serum, 2 mM glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin (growth medium). For experiments, cells between passage 7 and 15 were used at 70% confluence. Prior to all growth factor stimulation experiments, cells were starved for 24 h in Dulbecco\'s modified Eagle\'s medium containing 0.1% calf serum supplemented with 2 mM glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin (starve medium).

2.3. SDS--PAGE and western blotting {#s2c}
-----------------------------------

For experiments, cells were grown in 60 mm dishes and serum starved overnight in starve medium, then treated with Ang II (100 nM) or EGF (100 ng/mL) for the indicated time. Resveratrol (50 µM), vehicle control \[dimethyl sulfoxide (DMSO) 0.1%\], gp91ds-tat or the respective control peptide (100 µM) were added 30 min before stimulation. The VSMCs were pretreated with DPI (10 µM) for 1 h and NAC (10 mM) for 2 h before stimulation. Cells were then suspended in lysis buffer (50 mM HEPES, 50 mM NaCl, 5 mM EDTA, 10 mM sodium pyrophosphate, 50 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride and 1× complete protease inhibitor cocktail). Western blot analysis was performed as described previously.^[@CVQ355C4]^ Proteins of interest were visualized by the use of specific antibodies, an ECL system and a CCD camera (Fuji LAS 3000). Densitometric evaluation was performed by employing the AIDA image analyser 4.06 software (Raytest).

2.4. Measurement of intracellular ROS {#s2d}
-------------------------------------

For detection of the intracellular total ROS level, cells were grown in six-well plates and treated as indicated. Quiescent cells were washed once with pre-warmed HEPES buffered saline solution and incubated at 37°C for 30 min with 20 µM H~2~DCF-DA before stimulation with EGF (100 ng/mL) or Ang II (100 nM) for the indicated periods of time. Cells were then immediately analysed by flow cytometry (FACSCalibur, BD Bioscience). The mean fluorescence of 10 000 analysed cells (corrected for autofluorescence) was detected and used as a measurement for total ROS.

2.5. Determination of extracellular H~2~O~2~ level {#s2e}
--------------------------------------------------

The VSMCs were grown in 24-well plates and serum starved for 24 h. Cells were washed once with prewarmed phosphate-buffered saline, then krebs ringer phosphate glucose buffer containing the Amplex Red™ reagent was applied to the cells. Plates were incubated for 15 min at 37°C before VSMCs were stimulated as indicated. Resorufin, the fluorescent product, was measured in triplicate by a fluorescence multi-well plate reader with an excitation wavelength of 535 nm and an emission wavelength of 590 nm (Genios Pro, Tecan, Switzerland).

2.6. Transfection with small interfering RNA and quantitative real-time PCR {#s2f}
---------------------------------------------------------------------------

Five hours after seeding, VSMCs were transfected with small interfering RNA (siRNA; siNox4 from ThermoFisher Scientific, 50 nM; or scrambled siRNA control from Invitrogen) using Oligofectamine (Invitrogen) and Opti-MEM 1 (Gibco). For Nox4, the sequences used were sense 5′-ACUGAGGUACAGCUGGAUGUU-3′, and antisense 5′-CAUCCAGCUGUACCUCAGUUU-3′. Experiments were performed 72 h after siRNA transfection. The knock-down efficiency was verified by quantitative real-time PCR (qPCR). For this, mRNA was isolated using the pegGOLD total RNA Kit (Peqlab), and reverse transcription was performed using Superscript™ First-Strand Synthesis System (Invitrogen) according to the manufacturer\'s protocol. PCR was carried out with a LightCycler™ LC480 SYBR Green I Master reagent (Roche Diagnostics) and the LightCycler™ LC480 (Roche Diagnostics) system.

2.7. Synthesis of RV derivatives {#s2g}
--------------------------------

Methylated resveratrol derivatives were synthesized according to the literature.^[@CVQ355C24]^ Both ^1^H and ^13^C nuclear magnetic resonance spectra were recorded on a Bruker Advance DPx200 (200 and 50 MHz). Mass spectra (MS) were obtained by a Shimadzu (GC-17A; MS-QP5050A) spectrometer.

2.8. Statistical analysis {#s2h}
-------------------------

Results are expressed as means ± SEM. Statistical analysis was performed by ANOVA followed by Dunnett\'s multiple comparison test or by one-sample *t*-test using GraphPad PRISM, version 4.0 (GraphPad Software, San Diego, CA, USA). Differences with *P* \< 0.05 were considered significant.

3.. Results {#s3}
===========

3.1. Resveratrol reduces intracellular total ROS level and H~2~O~2~ release from VSMCs {#s3a}
--------------------------------------------------------------------------------------

First, we asked whether RV reduces intracellular total ROS level and/or H~2~O~2~ released from VSMCs and thereby leads to inhibition of Akt phosphorylation as described earlier.^[@CVQ355C4],[@CVQ355C5]^ Since NAD(P)H oxidases play a pivotal role in VSMC-derived ROS production, DPI, an unspecific inhibitor of flavin-containing enzymes including NAD(P)H oxidases,^[@CVQ355C25]^ was used as positive control. For detection of intracellular ROS, we loaded VSMCs with 20 µM H~2~DCF-DA. Angiotensin II (100 nM) was able to induce ROS production twofold compared with the vehicle control. Resveratrol (50 µM) and DPI (10 µM) pre-treatment reduced this ROS production almost to the basal level (*Figure [1](#CVQ355F1){ref-type="fig"}A*). In contrast, treatment of cells with 100 ng/mL EGF, a concentration that readily induced Akt phosphorylation, did not lead to a significant activation of intracellular ROS production in comparison with the vehicle control. Resveratrol and DPI, however, were able to inhibit basal intracellular ROS level by about 50% (*Figure [1](#CVQ355F1){ref-type="fig"}B*), verifying a strong ROS reducing activity for both compounds. Activation of the EGF-R has been reported to lead to increased extracellular H~2~O~2~ levels in A431 cells.^[@CVQ355C19]^ Therefore, we also measured extracellular H~2~O~2~ level using Amplex Red™. Both Ang II and EGF were able to induce the extracellular release of H~2~O~2~ in a time-dependent manner (*Figure [1](#CVQ355F1){ref-type="fig"}C* and *D*). Whereas EGF treatment led to a continuous accumulation of H~2~O~2~, which was highest after 15 min (20% above basal level), H~2~O~2~ production after Ang II stimulation peaked at 10 min (15% above basal level). Resveratrol reduced Ang II- and EGF-induced H~2~O~2~ but also basal levels far below control values (*Figure [1](#CVQ355F1){ref-type="fig"}C* and *D*). These findings demonstrate that RV blocks both H~2~O~2~ detected in the extracellular environment and intracellular total ROS produced in VSMCs. Figure 1Resveratrol (RV) diminishes intracellular reactive oxygen species (ROS) level and attenuates both basal and angiotensin II (Ang II)- or epidermal growth factor (EGF)-induced extracellular H~2~O~2~. Quiescent vascular smooth muscle cells (VSMCs) were pre-incubated with dichlorodihydrofluorescein-diacetate (H~2~DCF-DA; 20 µM, 15 min) and then incubated with 50 µM RV or vehicle control for 30 min or 10 µM diphenyleneiodonium (DPI) for 1 h and finally stimulated with 100 nM Ang II for 15 min (*A*) or 100 ng/mL EGF for 10 min (*B*). ROS production (equivalent to the amount of formed DCF) was analysed by flow cytometry. The average fluorescence signal obtained in the presence of Ang II or EGF was set to 100% (\*\**P* \< 0.01; one-way ANOVA vs. Ang II or EGF treatment, *n* = 3). Serum-starved VSMCs were stimulated in Amplex Red™ buffer with Ang II (100 nM; *C*) or EGF (100 ng/mL; *D*) for 5--15 min after pre-incubation with RV (50 µM) or vehicle control for 30 min. H~2~O~2~ production was quantified by fluorescence measurement. Absolute values were correlated to catalase-treated cells used as a negative control. Graphs show the relative extracellular H~2~O~2~ production expressed as a percentage of vehicle-treated control cells (open square, vehicle-treated cells; filled squares, RV-treated cells; \*\*\**P* \< 0.001; *t*-test, *n* = 4).

3.2. A Nox4 knock-down does not influence the phosphorylation of Akt in Ang II- or EGF-activated VSMCs {#s3b}
------------------------------------------------------------------------------------------------------

To investigate whether Nox4 is important for the EGF- or Ang II-induced signalling towards Akt in our cell system, Nox4 was knocked down by siRNA. After 72 h, Nox4 mRNA level was analysed by qPCR. The siRNA reduced the Nox4 mRNA level to 15% compared with scrambled control, whereas the mRNA level of Nox1 was unchanged (*Figure [2](#CVQ355F2){ref-type="fig"}A* and *B*). As expected, knock-down of Nox4 had no impact on the phosphorylation of Akt after Ang II (100 nM, 10 min) stimulation. Moreover, the inhibitory effect of RV on Akt phosphorylation remained unaffected (*Figure [2](#CVQ355F2){ref-type="fig"}C*). Interestingly, the EGF-induced Akt phosphorylation and the inhibitory effect of RV also remained unaltered in Nox4 knock-down cells (*Figure [2](#CVQ355F2){ref-type="fig"}D*). Thus, Nox4 seems not to be involved in Ang II- or EGF-mediated phosphorylation of Akt, and therefore Nox4-derived ROS are not a potential target of RV. Figure 2Ang II- and EGF-induced Akt phosphorylation and its inhibition by RV occur independent of Nox4. Knock-down of Nox4 was achieved by treating cells with 50 nM small interfering RNA (siRNA) against Nox4 or 50 nM scrambled control siRNA for 72 h. The mRNA was isolated, and expression of Nox4 and Nox1 detected by qPCR. Graphs (*A* and *B*) show mean + SEM of Nox4 mRNA (*A*) or Nox1 mRNA (*B*) level relating to 18S mRNA. Data were normalized by setting scrambled control to 100% (\*\*\**P* \< 0.001; *n* = 3). Serum-deprived Nox4 siRNA-treated cells (50 nM, 72 h) were pre-treated with RV (50 µM, 30 min) or vehicle control followed by stimulation with 100 nM Ang II for 10 min (*C*) or 100 ng/mL EGF for 5 min (*D*). Akt phosphorylation and tubulin (tub, serving as a loading control) were detected by western blot analysis. One representative blot out of three, which were densitometrically analysed, is shown. The graphs represent the mean densitometric values + SEM of three independent experiments. Akt phosphorylation in response to Ang II or EGF of scrambled control was set to 100% (\**P* \< 0.05, \*\**P* \< 0.01; one-way ANOVA, *n* = 3).

3.3. Down-regulation of Nox1 inhibits Akt phosphorylation in response to Ang II but not EGF stimulation {#s3c}
-------------------------------------------------------------------------------------------------------

In Ang II-activated VSMCs, Nox1 has been shown to be the major ROS-producing component necessary for the transactivation of the EGF-R, leading finally to Akt activation.^[@CVQ355C16]^ To the best of our knowledge, however, it is unknown whether EGF utilizes Nox1 to transduce its growth signal, although in transactivated settings prolonged Nox1 activation seems to need Rac1 activation via PI3K downstream of the EGF-R.^[@CVQ355C16]^ To inhibit Nox1 we employed 100 µM of the blocking peptide gp91ds-tat that prevents assembly of the Nox protein with cofactors^[@CVQ355C12]^ or a control peptide. As expected, gp91ds-tat pre-treatment led to an inhibition of Ang II-mediated Akt phosphorylation (*Figure [3](#CVQ355F3){ref-type="fig"}A*). In contrast to RV, gp91ds-tat also inhibited the phosphorylation of p38, a known redox-sensitive kinase, by more than 50% (*Figure [3](#CVQ355F3){ref-type="fig"}B*). In EGF-activated VSMCs, gp91ds-tat, in contrast to RV, had no effect on Akt phosphorylation (*Figure [3](#CVQ355F3){ref-type="fig"}C*). A putative effect of gp91ds-tat on p38 phosphorylation did not reach significance (*Figure [3](#CVQ355F3){ref-type="fig"}D*). The unspecific control peptide used had no influence on Akt or p38 phosphorylation in response to either stimulus (data not shown). These data show that Nox1 is important for Ang II- but not for EGF-mediated phosphorylation of Akt and p38. Inhibition of Nox1 is not able to mimic the effect of RV in our setting, and thus renders Nox1-derived ROS an unlikely target of RV. Figure 3Inhibition of Nox1 blunts phosphorylation of Akt and p38 induced by Ang II but does not alter EGF-induced Akt and p38 phosphorylation. Quiescent VSMCs were pre-treated with 100 µM of the gp91ds-tat blocking peptide (gp91ds), 50 µM RV or vehicle control for 30 min, and were then stimulated with 100 nM Ang II for 10 min (*A* and *B*) or 100 ng/mL EGF (*C* and *D*) for 5 min. Akt (*A* and *C*) and p38 phosphorylation (*B* and *D*) as well as tubulin (tub, as loading control) were detected by western blot analysis. One representative blot out of three, which were densitometrically analysed, is shown. The graphs depict the mean densitometric values + SEM of three independent experiments. Signals obtained in response to Ang II or EGF were set to 100% (\**P* \< 0.05, \*\**P* \< 0.01; n.s., not significant; one-way ANOVA vs. Ang II or EGF treatment, *n* = 3).

3.4. Both DPI and NAC inhibit Akt phosphorylation upon Ang II but not EGF stimulation {#s3d}
-------------------------------------------------------------------------------------

To further clarify the general dependency of EGF- and Ang II-induced signalling towards Akt and p38 on ROS we applied the Nox/flavoprotein inhibitor DPI (10 µM) and the precursor of glutathione, NAC (10 mM). We found that Ang II-induced phosphorylation of Akt was blocked by NAC as effectively as by RV, while DPI was less effective (*Figure [4](#CVQ355F4){ref-type="fig"}A*). In contrast to RV, which had no effect on the phosphorylation of p38 after Ang II stimulation, NAC and DPI were able to block the phosphorylation to basal levels (*Figure [4](#CVQ355F4){ref-type="fig"}B*). Phosphorylation of Akt upon EGF stimulation was inhibited effectively only by RV; NAC and DPI had no consistent inhibitory effect (*Figure [4](#CVQ355F4){ref-type="fig"}C*). Resveratrol, NAC or DPI did not inhibit p38 phosphorylation in response to EGF stimulation (*Figure [4](#CVQ355F4){ref-type="fig"}D*). These data indicate that Ang II, as described, utilizes ROS for its signal transduction towards Akt and p38, but EGF does not. Moreover, RV seems not to require its antioxidant activity to inhibit Akt phosphorylation. Figure 4DPI and NAC inhibit Ang II-induced phosphorylation of Akt and p38. Serum-deprived cells were pre-treated with 50 µM RV or vehicle control for 30 min, 10 µM DPI for 1 h or 10 mM NAC for 2 h, and then stimulated with 100 nM Ang II for 10 min (*A* and *B*), or 100 ng/mL EGF for 5 min (*C* and *D*). Lysates were subjected to western blot analysis using antibodies against pAkt (*A* and *C*), pp38 (*B* and *D*) and tubulin (tub). Representative blots out of three are shown. The graphs depict the mean + SEM of the densitometric analyses. Signals obtained in response to Ang II or EGF were set to 100% (\**P* \< 0.05, \*\**P* \< 0.01; n.s., not significant; one-way ANOVA vs. Ang II or EGF treatment, *n* = 3).

3.5. A non-antioxidant RV derivative inhibits Ang II and EGF-mediated Akt phosphorylation {#s3e}
-----------------------------------------------------------------------------------------

To confirm that RV, although redox-active, does not act as an antioxidant when inhibiting Akt phosphorylation we employed the following two non-antioxidant derivatives of RV: *trans*-3,5,4′-trimethoxystilbene (RV-3M) with all three hydroxyl groups methylated (*Figure [5](#CVQ355F5){ref-type="fig"}A*) and thus blunted redox activity,^[@CVQ355C26]^ and *trans*-3,5-dihydroxy-4′-methoxystilbene (RV-1M), methylated at the 4′-OH group only (*Figure [5](#CVQ355F5){ref-type="fig"}B*). Mono-methylation at the 4′-OH group renders RV largely redox inactive, since Queiroz *et al*. have recently shown that the prime antioxidant pharmacophore of RV is 4′-hydroxystilbene,^[@CVQ355C27]^ a finding that is also supported by others^[@CVQ355C26]^ and confirmed by our synthesized derivatives *in vitro* (see [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq355/DC1)). To test their redox activity in the presence of cells we used Amplex Red™ to detect extracellular H~2~O~2~ in the presence of RV or its derivatives, RV-3M and RV-1M. As expected, neither of the two derivatives was found to reduce extracellularly detected H~2~O~2~ significantly after stimulation of VSMCs with Ang II (*Figure [6](#CVQ355F6){ref-type="fig"}A*). Using Akt phosphorylation as read-out, RV-3M inhibited neither Ang II- nor EGF-induced Akt phosphorylation. Most interestingly, however, the derivative RV-1M, despite its lack of influence on H~2~O~2~, reduced phosphorylation of Akt in response to Ang II treatment by over 50%, which was comparable to RV-mediated inhibition. The EGF-induced phosphorylation of Akt was inhibited equally well by RV-1M compared with RV (*Figure [6](#CVQ355F6){ref-type="fig"}B* and *C*). These data clearly show that RV inhibits Akt phosphorylation by a mechanism that is not related to its antioxidant activity in both Ang II- and EGF-stimulated VSMCs. In contrast, the 3- and 5-OH groups of RV seem to be critically involved in mediating Akt inhibition. A consistent picture of redox-independent inhibition of Akt phosphorylation by RV and RV-1M was observed in human primary aortic smooth muscle cells (see [Supplementary material online, *Figure S2*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq355/DC1)). Figure 5Non-antioxidant derivatives of RV, *trans*-3,5,4′-trimethoxystilbene (RV-3M; *A*), and *trans*-3,5-dihydroxy-4′-methoxystilbene (RV-1M; *B*). Figure 6Non-antioxidant *trans*-3,5-dihydroxy-4′-methoxystilbene (RV-1M) inhibits phosphorylation of Akt after Ang II and EGF stimulation. (*A*)** **Starved VSMCs were stimulated in Amplex Red™ buffer with Ang II (100 nM) for 10 min after pre-incubation with RV or RV derivatives (RV, RV-3M, RV-1M; all 50 µM), or vehicle control for 30 min. H~2~O~2~ production was quantified by fluorescence measurement. The graph shows the relative extracellular H~2~O~2~ production (\*\**P* \< 0.01; one-way ANOVA vs. Ang II or EGF treatment, *n* = 3). (*B* and *C*). Serum-deprived cells were pre-treated with RV or RV derivatives, RV-3M or RV-1M, for 30 min (50 µM), followed by stimulation with 100 nM Ang II for 10 min (*B*), or 100 ng/mL EGF for 5 min (*C*). Protein levels were detected by western blot using antibodies against pAkt and tubulin. One representative blot out of three per stimulation is shown. Graphs show the mean + SEM of the densitometric signals; Ang II or EGF stimulation is set to 100% (\*\**P* \< 0.01; one-way ANOVA vs. Ang II or EGF treatment, *n* = 3).

4.. Discussion {#s4}
==============

We show here for the first time that although RV reduces total intracellular ROS level and extracellular H~2~O~2~ release, its antioxidant activity is not required for the inhibition of Akt phosphorylation in Ang II- or EGF-activated VSMCs. Moreover, we show that in VSMCs, EGF leads to an increase of extracellular H~2~O~2~ level but not of intracellular ROS production. This H~2~O~2~ seems not to play a major role for the signal transduction towards Akt and p38. Furthermore, we confirm that the Ang II-induced signalling pathways towards Akt and p38 require Nox1, and clearly show that Nox4 is not required for Ang II- or EGF-induced Akt activation.

Many pharmacological effects of RV are believed to be related to its antioxidant activity. In the field of cardiovascular diseases, Opie & Lecour recently summarized several of the RV effects that could be linked to an antioxidant action, including inhibition of low-density lipoprotein oxidation, inhibition of prostaglandin synthesis, down-regulation of intercellular adhesion molecule-1 and nuclear factor-κB, reduction of platelet activation and inhibition of Ang II-induced cardiomyocyte hypertrophy, and they speculated that even more RV effects might be redox related, although not proven yet.^[@CVQ355C2]^ Especially the report showing that RV inhibits Ang II-induced cardiomyocyte hypertrophy by its antioxidant activity may be of interest in our context. The authors show that RV (1--100 µM) inhibits Ang II-induced \[^3^H\]leucine incorporation as a measure for hypertrophy, beta-myosin heavy chain promoter activity, intracellular ROS level and ERK phosphorylation (although not examining other kinases) in cardiomyocytes. To link the antioxidant activity to the antihypertrophic effect of RV, they show that RV and the antioxidant NAC inhibit Ang II- or H~2~O~2~-induced \[^3^H\]leucine incorporation in cardiomyocytes comparably.^[@CVQ355C28]^ In some parts, the above report is in agreement with this and previous studies of our group, although we used VSMCs instead of cardiomyocytes; we found an inhibition of Ang II-induced hypertrophy measured by \[^3^H\]leucine incorporation^[@CVQ355C4]^ and now also ROS production by RV. Next to a minor effect on ERK phosphorylation, we found a strong inhibition of the PI3K--Akt pathway leading more downstream to an effective inhibition of p70 S6 kinase important for cellular hypertrophy.^[@CVQ355C4]^ Here we show, however, that inhibition of ROS and Akt phosphorylation are two parallel events mediated by RV that could not be causally linked in our system.

Our data also imply that the transduction of the signal induced by EGF in VSMCs is less redox dependent than that of Ang II, at least towards Akt and p38. Indeed, data regarding the ROS production of the EGF-activated (not transactivated) EGF-R and their importance for subsequent signal transduction are limited. The first report showing an intracellular increase in H~2~O~2~ production in response to EGF used epithelial A431 cells and concentrations of EGF as high as 500 ng/mL for stimulation.^[@CVQ355C29]^ Halvey *et al*.,^[@CVQ355C20]^ also detecting an increase of intracellular ROS after EGF stimulation in HaCaT cells, still used 200 ng/mL EGF. In agreement with our data, DeYulia *et al*.^[@CVQ355C19]^ showed in 293T cells transiently transfected with EGF-R that the addition of EGF (50 ng/mL) results in elevated extracellular H~2~O~2~. They even found that solely the receptor--ligand interaction using isolated proteins was sufficient to produce H~2~O~2~. The exact mechanism by which ROS is produced, however, remained elusive. Regarding the ROS source that might be used by the EGF-R to transduce the EGF signal, Chen *et al*. proposed Nox4 that is localized at the endoplasmic reticulum and is critical for the regulation of PTP1B. Using human aortic endothelial cells (HAECs), and for transfection studies COS-7 cells, they suggest that Nox4-mediated oxidation and inactivation of PTP1B in the endoplasmic reticulum serves as a regulatory switch for EGF-R trafficking that terminates the EGF signal.^[@CVQ355C30]^ Moreover, both the activated EGF-R as well as Nox4 were shown to be localized at focal adhesions in VSMCs.^[@CVQ355C31]^ Knocking down Nox4 in our system, however, had no influence on EGF- as well as Ang II-induced Akt phosphorylation, which excludes Nox4 as essential mediator of signal transduction towards Akt downstream of the AT~1~- and EGF-R as well as a potential target of RV.

While the impact of Nox4-derived ROS for a variety of physiological processes, including cell growth, death, and differentiation is not completely understood, the role of Nox1 in VSMC is much better defined.^[@CVQ355C16]^ Nox1-derived ROS was shown to regulate smooth muscle cell growth (hypertrophy and hyperplasia) and migration. The best-studied mechanism by which Nox1 is activated is that via the AT~1~ receptor by Ang II, including activation of phospholipase C and subsequently protein kinase C that phosphorylates p47phox, a regulatory subunit of Nox1. Transactivation of the EGF-R leads to a PI3K-dependent activation of Rac1 that is required for continued activation of Nox1 by Ang II.^[@CVQ355C16]^ Our data presented here again verify this model; the blocking peptide gp91ds-tat effectively inhibited the Ang II-induced signalling towards Akt and p38. In contrast, EGF-mediated phosphorylation of Akt and p38 was not significantly altered. We, therefore, excluded a Nox1-dependent mechanism activating Akt or p38 downstream of the EGF-R in our cells.

Several reports suggest an influence of RV on NAD(P)H oxidases in non-phagocytic cells.^[@CVQ355C32]--[@CVQ355C34]^ In our experimental set-up, however, neither knock-down of Nox4 nor inhibition of Nox1 assembly could mimic the RV effect. In addition, previous studies showed that RV was unable to inhibit the transactivation of the EGF-R in Ang II-activated VSMCs,^[@CVQ355C5]^ a process highly regulated by Nox1. Nevertheless, it remains conceivable that RV contributes to the inhibition of Nox1-derived ROS production by the inhibition of PI3K-dependent Rac1 at later time points.

The strongest argument against a redox-dependent mechanism of the inhibition by RV of Ang II- or EGF-induced Akt activation came from RV derivatives that were not acting as antioxidants but were highly effective in inhibiting Akt phosphorylation (*Figure [6](#CVQ355F6){ref-type="fig"}*). Most interestingly, we found that the hydroxyl groups in the 3- and 5-positions are sufficient to block Ang II- or EGF-induced Akt phosphorylation. Although not detected, we cannot completely exclude the possibility that small or local rises in intracellular H~2~O~2~ are quenched by these remaining two hydroxyl groups.

In summary, we could verify that Nox1 but not Nox4 is important for the Ang II-induced activation of Akt and p38 in VSMCs. The signalling triggered by EGF downstream of the EGF-R towards Akt and p38 phosphorylation seems to occur independently of Nox1, Nox4 or in general of ROS. Most interestingly, we showed that RV, although reducing intracellular ROS and extracellular H~2~O~2~ levels in VSMCs, does not use an antioxidant mechanism to inhibit Akt phosphorylation in Ang II- or EGF-activated VSMCs.

Supplementary material {#s5}
======================

[Supplementary material is available at *Cardiovascular Research* online](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq355/DC1).
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